Literature DB >> 9160114

Anti-adhesion therapy.

C J Cornejo1, R K Winn, J M Harlan.   

Abstract

Mesh:

Substances:

Year:  1997        PMID: 9160114     DOI: 10.1016/s1054-3589(08)60070-8

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


× No keyword cloud information.
  6 in total

1.  Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.

Authors:  Danielle G Souza; Riccardo Bertini; Angelica T Vieira; Fernando Q Cunha; Steve Poole; Marcello Allegretti; Francesco Colotta; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2004-08-09       Impact factor: 8.739

2.  Anti-adhesion molecule therapy for inflammatory bowel disease.

Authors:  Subrata Ghosh; Remo Panaccione
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

3.  NF-kappaB plays a major role during the systemic and local acute inflammatory response following intestinal reperfusion injury.

Authors:  Danielle G Souza; Angélica T Vieira; Vanessa Pinho; Lirlândia P Sousa; Anderson A Andrade; Cláudio A Bonjardim; Michael McMillan; Michael Kahn; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

4.  Role of tachykinin NK receptors on the local and remote injuries following ischaemia and reperfusion of the superior mesenteric artery in the rat.

Authors:  Danielle G Souza; Vanessa A Mendonça; Maria Salete de A Castro; Steve Poole; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 5.  Adhesion molecules in inflammatory diseases.

Authors:  R González-Amaro; F Díaz-González; F Sánchez-Madrid
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

6.  Effects of the PAF receptor antagonist UK74505 on local and remote reperfusion injuries following ischaemia of the superior mesenteric artery in the rat.

Authors:  D G Souza; D C Cara; G D Cassali; S F Coutinho; M R Silveira; S P Andrade; S P Poole; M M Teixeira
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.